Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients

Journal of Immunotherapy

Volumn 32, Issue 4, 2009, Pages 415-423

  Besser, Michal J ^a   Shapira Frommer, Ronnie ^b   Treves, Avraham J ^c   Zippel, Dov ^d   Itzhaki, Orit ^a   Schallmach, Ester ^a   Kubi, Adva ^a   Shalmon, Bruria ^e   Hardan, Izhar ^f   Catane, Raphael ^b   Segal, Eran ^g   Markel, Gal ^a   Apter, Sara ^h   Nun, Alon Ben ^a   Kuchuk, Iryna ^b   Shimoni, Avichai ^f   Nagler, Arnon ^f   Schachter, Jacob ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b Oncology Division   (Israel)

^c Sheba Cancer Research Center   (Israel)

^d Departments of Surgical Oncology   (Israel)

^e Departments of Pathology   (Israel)

^f Bone Marrow Transplantation   (Israel)

^g ICU   (Israel)

^h Maccabi Sick Fund   (Israel)

Author keywords

Adoptive cell therapy; Interleukin 2; Melanoma; Tumor infiltrating lymphocytes

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; ACICLOVIR; ALKYLATING AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; FLUCONAZOLE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; VIDARABINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSTIMULATION; IN VITRO STUDY; KIDNEY FAILURE; LUNG CONGESTION; LYMPHOCYTOPENIA; MALE; MELANOMA; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; AGED; BIOSYNTHESIS; CYTOTOXICITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MIDDLE AGED; SKIN TUMOR; TRANSPLANTATION;

ACYCLOVIR; ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIVIRAL AGENTS; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLUCONAZOLE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; VIDARABINE;

EID: 67449092903     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819c8bda     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther. 2006;19:19-25.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012.
4. Rosenberg SA, Yang JA, Nicholas PR. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10: 909-915.
5. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(suppl 1): S11-S14.
6. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
7. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299-308.
8. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphode-pleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23: 2346-2357.
9. Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Semin Oncol. 2007;34:524-531. Review.
10. Richards J, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992;10:1338-1343.
11. Khayat D, Borel C, Tourani J, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993;11:2173-2180.
12. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759.
13. Bar J, Yerushalmi R, Shapira-Frummer R, et al. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma. Oncol Rep. 2008;20:1533-1538.
14. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology. Group J Clin Oncol. 2008;26: 5748-5754.
15. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742-751.
16. Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007;30:123-129.
17. Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175:7046-7052.
18. Powell DJ Jr, Dudley ME, Robbins PF, et al. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005;105:241-250.
19. Rosenberg SA, Dudley M. Cancer regression in patients with metastatic melanoma after transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci. 2004;101(suppl 2): 14639-14645.
20. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003; 26:332-342.
21. Besser MJ, Treves AJ, Itzhaki O, et al. Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba medical center. Isr Med Assoc J. 2006; 8:164-168.
22. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-241.
23. Dudley ME, Ngo LT, Westwood J, et al. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J Sci Am. 2000;6:69-77.
24. Schallmach E, Sareli R, Besser MJ, et al. Collection of largescale expanded lymphocyte cultures for adoptive immunotherapy using a COBE spectra apheresis machine. J Immunother. 2008;31:563-568.
25. Roitberg-Tambur A, Witt CS, Friedmann A, et al. Comparative analysis of HLA polymorphism at the serologic and molecular level in Moroccan and Ashkenazi Jews. Tissue Antigens. 1995;46:104-110.
26. Barth RJ Jr, Mulé JJ, Spiess PJ, et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med. 1991;173:647-658.
27. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med. 2001;7:1159-1162.
28. Arina A, Murillo O, Hervás-Stubbs S, et al. The combined actions of NK and T lymphocytes are necessary to reject an EGFP + mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer. 2007;121: 1282-1295.
29. Buhtoiarov IN, Lum H, Berke G, et al. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol. 2005;174:6013-6022.
30. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
31. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
32. Heemskerk B, Liu K, Dudley ME, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008;5:496-510.